Orchestra BioMed Holdings, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Orchestra BioMed Holdings, Inc. (OBIO) holds an ST Score of 51.7 out of 100 (C+), with its strongest factor being Forecast (A+) and its weakest Growth (D-). Analysts rate OBIO Buy across 6 ratings with a $11.00 average price target (+0.8% vs the current $6.25).
- Strongest
- ForecastA+
- Weakest
- GrowthD-
All factor grades
- ForecastA+
- MomentumA
- ValuationB-
- Financial StrengthC+
- ProfitabilityD+
- GrowthD-
- Piotroski3/9
Contact
OBIO stock: frequently asked questions
What is OBIO's ST Score?
Orchestra BioMed Holdings, Inc. (OBIO) has an ST Score of 51.7 out of 100, an overall grade of C+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is OBIO a buy, sell, or hold?
Wall Street's consensus rating on OBIO is Buy based on 6 analyst ratings. Our own ST Score grades it C+ (51.7/100). This is data, not investment advice — always do your own research.
What is OBIO's valuation grade?
Orchestra BioMed Holdings, Inc. (OBIO) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is OBIO's growth grade?
Orchestra BioMed Holdings, Inc. (OBIO) earns a growth grade of D-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is OBIO's profitability grade?
Orchestra BioMed Holdings, Inc. (OBIO) earns a profitability grade of D+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is OBIO's financial strength grade?
Orchestra BioMed Holdings, Inc. (OBIO) earns a financial strength grade of C+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for OBIO?
The average analyst price target for Orchestra BioMed Holdings, Inc. (OBIO) is $11.00 from 6 analysts, which is +0.8% versus the recent price of $6.25.
What is OBIO's Piotroski score?
Orchestra BioMed Holdings, Inc. (OBIO) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.